NCT04116320 2025-07-14
AM-003
University of Virginia
Phase 1 Terminated
Clinical Trials
8 trialsNCT01810016 2022-10-12
NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic Melanoma
Ludwig Institute for Cancer Research
Phase 1 Terminated
NCT03597282 2020-09-03
A Personal Cancer Vaccine (NEO-PV-01) and APX005M or Ipilimumab With Nivolumab in Patients With Advanced Melanoma
BioNTech SE
Phase 1 Terminated
NCT01437605 2019-12-20
Phase II Study to Assess the Safety and Immunogenicity of recMAGE-A3+AS15 ASCI With or Without Poly IC:LC
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Terminated
NCT02061449 2018-12-24
Poly ICLC, Radiation, and Romidepsin for Advanced Cutaneous T Cell Lymphoma
NYU Langone Health
Phase 1 Terminated
NCT01984892 2018-01-23
Hiltonol
Icahn School of Medicine at Mount Sinai
Phase 2 Terminated
NCT02413827 2017-04-07
A Study of Varlilumab (Anti-CD27) and Ipilimumab and CDX-1401 in Patients With Unresectable Stage III or IV Melanoma
Celldex Therapeutics
Phase 1/2 Terminated
NCT01783431 2015-10-02
Study of Vaccination With Poly-ICLC and Peptide-pulsed Dendritic Cells
Medical University of South Carolina
Phase 1 Terminated